Insulet Corp Files 2024 Proxy Statement

Ticker: PODD · Form: DEF 14A · Filed: 2024-04-09T00:00:00.000Z

Sentiment: neutral

Topics: proxy-statement, annual-meeting, sec-filing

TL;DR

Insulet's proxy statement is out for the May 22 meeting - shareholders vote soon!

AI Summary

Insulet Corporation filed its DEF 14A proxy statement on April 9, 2024, for its annual meeting on May 22, 2024. The filing outlines the information required for the proxy statement, including details for shareholders to vote on company matters. The company is based in Acton, MA, and operates in the surgical and medical instruments sector.

Why It Matters

This filing is crucial for shareholders as it details the agenda and proposals for the upcoming annual meeting, allowing them to make informed voting decisions on the company's future direction.

Risk Assessment

Risk Level: low — This is a routine annual filing providing information to shareholders and does not inherently present new risks.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of a DEF 14A filing?

A DEF 14A filing, also known as a Proxy Statement, is required by the SEC to provide shareholders with information they need to vote at an annual or special meeting of shareholders.

When is Insulet Corporation's annual meeting scheduled?

Insulet Corporation's annual meeting is scheduled for May 22, 2024.

What is Insulet Corporation's business address?

Insulet Corporation's business address is 100 Nagog Park, Acton, MA 01720.

What is the filing date of this DEF 14A?

This DEF 14A filing was made on April 9, 2024.

What industry does Insulet Corporation operate in?

Insulet Corporation operates in the Surgical & Medical Instruments & Apparatus industry, with SIC code 3841.

From the Filing

0001140361-24-018846.txt : 20240409 0001140361-24-018846.hdr.sgml : 20240409 20240409160604 ACCESSION NUMBER: 0001140361-24-018846 CONFORMED SUBMISSION TYPE: DEF 14A PUBLIC DOCUMENT COUNT: 63 CONFORMED PERIOD OF REPORT: 20240522 FILED AS OF DATE: 20240409 DATE AS OF CHANGE: 20240409 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INSULET CORP CENTRAL INDEX KEY: 0001145197 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 043523891 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEF 14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-33462 FILM NUMBER: 24832748 BUSINESS ADDRESS: STREET 1: 100 NAGOG PARK CITY: ACTON STATE: MA ZIP: 01720 BUSINESS PHONE: 978-600-7000 MAIL ADDRESS: STREET 1: 100 NAGOG PARK CITY: ACTON STATE: MA ZIP: 01720 DEF 14A 1 ny20016889x1_def14a.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.  ) ☑ Filed by the Registrant ​ ​   ☐ Filed by a Party other than the Registrant Check the appropriate box:   ☐ ​ ​ Preliminary Proxy Statement   ☐ ​ ​ CONFIDENTIAL, FOR USE OF THE COMMISSION ONLY (AS PERMITTEDBY RULE 14a-6(e)(2)) ☑ ​ ​ Definitive Proxy Statement   ☐ ​ ​ Definitive Additional Materials   ☐ ​ ​ Soliciting Material under §240.14a-12 Insulet Corporation (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): ☑ ​ ​ No fee required.   ☐ ​ ​ Fee paid previously with preliminary materials.   ☐ ​ ​ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. TABLE OF CONTENTS   TABLE OF CONTENTS   TABLE OF CONTENTS   ​ ​   ​ ​   ​ Dear Shareholders, ​ ​ This past year has been marked by exceptional financial success and operational milestones for Insulet. Our dedicated global teams are deeply committed to our mission of improving the lives of people with diabetes. Thanks to their efforts, we achieved, and in many cases exceeded, our key strategic objectives. ​ ​ Revolutionary Product Drives Financial Results . Omnipod® 5, our ground-breaking automated insulin delivery (AID) system, continues to surpass expectations, playing a pivotal role in driving 30% revenue growth in 2023, which led to our eighth consecutive year of significant revenue growth. Omnipod 5 also drove our record number of new customer starts in 2023, and it was the most prescribed AID system in the U.S. (1) Through our team’s exceptional execution and unwavering commitment to innovation, we reinforced our status as a leader in AID technology. In 2023, we leveraged our many competitive advantages, enabling us to offer this life-changing innovation to more people with diabetes worldwide. Insulet also became free cash flow positive in 2023 and significantly expanded margins, which further strengthens our financial position, providing the flexibility to increase our investments throughout the business to drive sustainable long-term growth, operating leverage, and continued free cash flow. ​ Helping More People. We take great pride in the remarkable impact the entire Omnipod product platform is having on individuals with diabetes. We recently reached a significant milestone, with approximately 425,000 active global Omnipod customers, representing approximately 25% annual growth. Notably, nearly 250,000 customers are benefiti

View on Read The Filing